Lineage Cell Therapeutics, Inc.

NYSE American: LCTX
Share price (12/20/24): $0.56
Market cap (12/20/24): $105 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

from 425 90 pages Agreement and Plan of Merger by and Among Biotime, Inc., Patrick Merger Sub, Inc. and Asterias Biotherapeutics, Inc. Dated as of November 7, 2018

from 8-K 90 pages Agreement and Plan of Merger by and Among Biotime, Inc., Patrick Merger Sub, Inc. and Asterias Biotherapeutics, Inc. Dated as of November 7, 2018

from DFAN14A 252 pages Asset Contribution Agreement by and Among: Biotime, Inc., a California Corporation, Biotime Acquisition Corporation, a Delaware Corporation, and Geron Corporation, a Delaware Corporation Dated as of January 4, 2013

from DEFA14A 240 pages Asset Contribution Agreement by and Among: Biotime, Inc., a California Corporation, Biotime Acquisition Corporation, a Delaware Corporation, and Geron Corporation, a Delaware Corporation Dated as of January 4, 2013

from 8-K 240 pages Asset Contribution Agreement by and Among: Biotime, Inc., a California Corporation, Biotime Acquisition Corporation, a Delaware Corporation, and Geron Corporation, a Delaware Corporation Dated as of January 4, 2013

from 10-K 36 pages Agreement and Plan of Merger

from SC 13D ~5 pages Consulting Agreement